<div id="readability-page-1"><p>Wesbanco Bank Inc. lessened its stake in shares of  GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 73.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,000 shares of the company's stock after selling 32,500 shares during the quarter. Wesbanco Bank Inc.'s holdings in GRAIL were worth $1,027,000 at the end of the most recent reporting period.</p><ul><li>Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025</li></ul><p>A number of other large investors have also recently bought and sold shares of the stock. Farallon Capital Management LLC lifted its stake in shares of  GRAIL by 168.7% during the 3rd quarter. Farallon Capital Management LLC now owns 1,349,000 shares of the company's stock worth $79,766,000 after purchasing an additional 847,000 shares during the period.  Bank of America Corp DE lifted its stake in shares of  GRAIL by 121.0% during the 3rd quarter. Bank of America Corp DE now owns 335,365 shares of the company's stock worth $19,830,000 after purchasing an additional 183,611 shares during the period.  Allianz Asset Management GmbH lifted its stake in shares of  GRAIL by 145.9% during the 3rd quarter. Allianz Asset Management GmbH now owns 294,835 shares of the company's stock worth $17,434,000 after purchasing an additional 174,959 shares during the period.  Vanguard Group Inc. lifted its stake in shares of  GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company's stock worth $169,535,000 after purchasing an additional 163,790 shares during the period.  Finally, Invesco Ltd. lifted its stake in shares of  GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company's stock worth $11,244,000 after purchasing an additional 157,780 shares during the period. </p><h2>Insider Buying and Selling</h2><p>In related news, President Joshua J. Ofman sold 61,665 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $3,078,316.80. Following the transaction, the president directly owned 371,216 shares of the company's stock, valued at approximately $18,531,102.72. This trade represents a 14.25% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Aaron Freidin sold 45,806 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $2,286,635.52. Following the completion of the sale, the chief financial officer owned 260,669 shares of the company's stock, valued at approximately $13,012,596.48. This represents a 14.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 310,267 shares of company stock valued at $15,485,396. 1.83% of the stock is currently owned by company insiders. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>A number of brokerages have weighed in on GRAL. Wall Street Zen raised GRAIL from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Mizuho began coverage on GRAIL in a research note on Friday, April 10th. They set a &#34;neutral&#34; rating and a $58.00 price target on the stock. Piper Sandler increased their price target on GRAIL from $54.00 to $56.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of GRAIL in a research note on Tuesday, April 21st. Finally, TD Cowen increased their target price on GRAIL from $65.00 to $69.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat, GRAIL presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $67.88.</p><p><b>Get Our Latest Analysis on GRAL</b></p><h2>GRAIL Stock Performance</h2><ul><li>3 Medical Technology Stocks Outperforming in 2025</li></ul><p>Shares of GRAL opened at $61.64 on Monday. The firm has a market capitalization of $2.65 billion, a P/E ratio of -5.94 and a beta of 3.03. The stock's fifty day simple moving average is $51.05 and its 200 day simple moving average is $78.44. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84. </p><p>GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, topping the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.79 million for the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. Sell-side analysts predict that  GRAIL, Inc. will post -11.09 earnings per share for the current year. </p><h2>GRAIL Profile</h2> (Free Report)<p>GRAIL, Inc <span>NASDAQ: GRAL<span></span></span> is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.  </p><p>Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.</p><h2>See Also</h2><ul><li>Five stocks we like better than GRAIL</li><li>3 Companies Quietly Essential to Data Center and AI Operations</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GRAIL Right Now?</h2><p>Before you consider GRAIL, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.</p><p>While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GRAL

LABU

ARKG

SBIO

IDNA

<p>Wesbanco Bank Inc. reduced its stake in GRAIL, Inc. (NASDAQ:GRAL) by 73% in Q4, now holding 12,000 shares after selling 32,500. Other investors like Farallon Capital and Bank of America increased their stakes significantly. Insider sales included President Joshua J. Ofman and CFO Aaron Freidin, who sold shares at around $49.92. Analyst ratings for GRAIL vary, with a consensus rating of "Hold" and a target price of $67.88. GRAIL shares opened at $61.64, with a market cap of $2.65 billion and a 12-month range of $29.95 to $118.84.</p>

Market Beat

GRAIL

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Genomics Immunology and Healthcare ETF

WesBanco

Annaly Capital Mgmt

Sculptor Capital

Sun Capital Management Corp.

Nano Labs

Bank of America

Allianz SE

Allianz

Allianz Technology Trust PLC

The Vanguard Group, Inc.

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

Invesco

Zensho Holdings Co., Ltd.

Financial Street

Charter Hall Long WALE REIT

Mizuho Financial

Mizuho Financial Group, Inc.

Piper Sandler Cos

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

Toronto Dominion Bank

Bank of Montreal

Canadian Imperial Bank Comm

Wesbanco Pref Shares 7.375 WSBC Perp 10/01/30

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AmpliTech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Charter Hall Retail REIT

Charter Hall Group

Charter Hall Social Infrastructure REIT

GRAIL, Inc. $GRAL Shares Sold by Wesbanco Bank Inc.